Dr. Xie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2017 - 2020
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Cleveland Clinic Lerner College of MedicineClass of 2014, MD
Princeton UniversityPhD, Organic Chemistry, 2004 - 2009- Fudan UniversityBS, Chemistry, 2000 - 2004
Certifications & Licensure
FL State Medical License 2020 - 2026
MN State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Rapid and Sensitive Detection of Thrombospondin-2 Using Nanoparticle Sensors for Cancer Screening and Prognosis.Maziyar Kalateh Mohammadi, Seyedsina Mirjalili, Md Ashif Ikbal, Hao Xie, Chao Wang
Micromachines. 2025-03-20 - Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.Khalid Jazieh, Jill Tsai, Sheila Solomon, Mojun Zhu, Frank A Sinicrope
Clinical Cancer Research. 2025-03-03 - Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer.Shahla Bari, Marco Matejcic, Richard D Kim, Hao Xie, Ibrahim H Sahin
JAMA Network Open. 2025-03-03
Lectures
- Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Researchers Identify Mutations Linked to Primary KRAS G12C Inhibitor ResistanceMarch 5th, 2025- Certain Genetic Alterations May Contribute to Primary Resistance of Certain Cancers to KRAS G12C InhibitorsMarch 3rd, 2025
- Key Genetic Changes May Drive Primary Resistance of Colorectal and Pancreatic Cancers to KRAS G12C InhibitorsMarch 3rd, 2025
- Join now to see all
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
